Copy number heterogeneity identifies ER+ breast cancer patients that do not benefit from adjuvant endocrine therapy
- 21 July 2022
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 127 (7) , 1332-1339
Abstract
Background Endocrine therapy forms the backbone of adjuvant treatment for oestrogen-receptor-positive (ER+) breast cancer. However, it remains unclear whether adjuvant treatment improves survival rates in low-risk patients. Low intra-tumour heterogeneity (ITH) has been shown to confer low risk for recurrent disease. Here, it is studied if chromosomal copy-number ITH (CNH) can identify low-risk ER+, lymph-node-negative breast cancer patients who do not benefit from adjuvant endocrine therapy. Methods Lymph-node-negative ER+ patients from the observational METABRIC dataset were retrospectively analysed (n = 708). CNH was determined from a single bulk copy-number measurement for each patient. Survival rates were compared between patients that did or did not receive adjuvant endocrine therapy for CNH-low, middle and high groups with Cox proportional-hazards models, using propensity-score weights to correct for confounders. Results Adjuvant endocrine therapy improved the relapse-free survival (RFS) for CNH-high patients treatment (HR = 0.55), but not for CNH-low patients treatment (HR = 0.88). For CNH-low patients adjuvant endocrine therapy was associated with impaired OS (HR = 1.62). Conclusions This retrospective study of lymph-node-negative, ER+ breast cancer finds that patients identified as low risk using CNH do not benefit from adjuvant endocrine therapy.Keywords
All Related Versions
Funding Information
- Amsterdam UMC, Oncode, Amsterdam Gastroenterology & Metabolism
- Amsterdam UMC, Oncode, Amsterdam Gastroenterology & Metabolism
- KWF Kankerbestrijding (12215)
- Amsterdam UMC, Oncode, Amsterdam Gastroenterology & Metabolism
This publication has 34 references indexed in Scilit:
- Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trialsThe Lancet, 2015
- Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtypeAnnals of Oncology, 2015
- Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused UpdateJournal of Clinical Oncology, 2014
- Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trialThe Lancet, 2013
- The performance of different propensity score methods for estimating marginal hazard ratiosStatistics in Medicine, 2012
- Why Your New Cancer Biomarker May Never Work: Recurrent Patterns and Remarkable Diversity in Biomarker FailuresCancer Research, 2012
- The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroupsNature, 2012
- PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancerBreast Cancer Research, 2010
- Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifenBMC Genomics, 2008
- Competing Causes of Death From a Randomized Trial of Extended Adjuvant Endocrine Therapy for Breast CancerJNCI: Journal of the National Cancer Institute, 2008